Hyloris Pharmaceuticals SA
XBRU:HYL

Watchlist Manager

Hyloris Pharmaceuticals SA

XBRU:HYL

Watchlist

Dividends

Discount Rate

Price: 4.3 EUR -6.72% Market Closed

Market Cap: 120.4m EUR

Have any thoughts about
Hyloris Pharmaceuticals SA?

Write Note

Write Note Create Alert Ask AI

Add Note Why Create Notes?

Capture your thoughts

Note Buy Sell Hold Pass

US	Johnson & Johnson NYSE:JNJ	Pharmaceuticals
US	Estee Lauder Companies Inc NYSE:EL	Consumer products
US	Exxon Mobil Corp NYSE:XOM	Energy
US	Church & Dwight Co Inc NYSE:CHD	Consumer products
US	Pfizer Inc NYSE:PFE	Pharmaceuticals
US	American Express Co NYSE:AXP	Financial Services
US	Nike Inc NYSE:NKE	Textiles, Apparel & Luxury Goods
US	Visa Inc NYSE:V	Technology
CN	Alibaba Group Holding Ltd NYSE:BABA	Retail
US	3M Co NYSE:MMM	Industrial Conglomerates
US	JPMorgan Chase & Co NYSE:JPM	Banking
US	Coca-Cola Co NYSE:KO	Beverages
US	Target Corp NYSE:TGT	Retail
US	Walt Disney Co NYSE:DIS	Media
US	Mueller Industries Inc NYSE:MLI	Machinery
US	PayPal Holdings Inc NASDAQ:PYPL	Technology

Add Price Alert

Price Target:

Last Price: 4.3 EUR

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch

Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?

Back

Delete Note

Do you really want to delete this note?
This action cannot be undone.

Remove price alert for reaching

Delete

Cancel

HYL Alert

Hyloris Pharmaceuticals SA

4.3

-0.31 (-6.72%)

52 Week Range	3.75 13.3
Price Target

We'll email you a reminder when the closing price reaches EUR.

Save Alert

Choose the stock you wish to monitor with a price alert.

	Johnson & Johnson NYSE:JNJ	US
	Estee Lauder Companies Inc NYSE:EL	US
	Exxon Mobil Corp NYSE:XOM	US
	Church & Dwight Co Inc NYSE:CHD	US
	Pfizer Inc NYSE:PFE	US
	American Express Co NYSE:AXP	US
	Nike Inc NYSE:NKE	US
	Visa Inc NYSE:V	US
	Alibaba Group Holding Ltd NYSE:BABA	CN
	3M Co NYSE:MMM	US
	JPMorgan Chase & Co NYSE:JPM	US
	Coca-Cola Co NYSE:KO	US
	Target Corp NYSE:TGT	US
	Walt Disney Co NYSE:DIS	US
	Mueller Industries Inc NYSE:MLI	US
	PayPal Holdings Inc NASDAQ:PYPL	US

Delete Alert

This alert will be permanently deleted.

Remove note

Delete

Cancel

Ask me anything about

Hyloris Pharmaceuticals SA

What unique competitive advantages
does Hyloris Pharmaceuticals SA hold over its rivals?

What risks and challenges
does Hyloris Pharmaceuticals SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of Hyloris Pharmaceuticals SA.

What unique competitive advantages
does Hyloris Pharmaceuticals SA hold over its rivals?

What risks and challenges
does Hyloris Pharmaceuticals SA face in the near future?

Has there been any significant insider trading activity
in Hyloris Pharmaceuticals SA recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Hyloris Pharmaceuticals SA.

Provide P/S
for Hyloris Pharmaceuticals SA.

Provide P/E
for Hyloris Pharmaceuticals SA.

Provide P/OCF
for Hyloris Pharmaceuticals SA.

Provide P/FCFE
for Hyloris Pharmaceuticals SA.

Provide P/B
for Hyloris Pharmaceuticals SA.

Provide EV/S
for Hyloris Pharmaceuticals SA.

Provide EV/GP
for Hyloris Pharmaceuticals SA.

Provide EV/EBITDA
for Hyloris Pharmaceuticals SA.

Provide EV/EBIT
for Hyloris Pharmaceuticals SA.

Provide EV/OCF
for Hyloris Pharmaceuticals SA.

Provide EV/FCFF
for Hyloris Pharmaceuticals SA.

Provide EV/IC
for Hyloris Pharmaceuticals SA.

Show me price targets
for Hyloris Pharmaceuticals SA made by professional analysts.

What are the Revenue projections
for Hyloris Pharmaceuticals SA?

How accurate were the past Revenue estimates
for Hyloris Pharmaceuticals SA?

What are the Net Income projections
for Hyloris Pharmaceuticals SA?

How accurate were the past Net Income estimates
for Hyloris Pharmaceuticals SA?

What are the EPS projections
for Hyloris Pharmaceuticals SA?

How accurate were the past EPS estimates
for Hyloris Pharmaceuticals SA?

What are the EBIT projections
for Hyloris Pharmaceuticals SA?

How accurate were the past EBIT estimates
for Hyloris Pharmaceuticals SA?

Compare the revenue forecasts
for Hyloris Pharmaceuticals SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Hyloris Pharmaceuticals SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Hyloris Pharmaceuticals SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Hyloris Pharmaceuticals SA compared to its peers.

Compare the P/E ratios
of Hyloris Pharmaceuticals SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Hyloris Pharmaceuticals SA with its peers.

Analyze the financial leverage
of Hyloris Pharmaceuticals SA compared to its main competitors.

Show all profitability ratios
for Hyloris Pharmaceuticals SA.

Provide ROE
for Hyloris Pharmaceuticals SA.

Provide ROA
for Hyloris Pharmaceuticals SA.

Provide ROIC
for Hyloris Pharmaceuticals SA.

Provide ROCE
for Hyloris Pharmaceuticals SA.

Provide Gross Margin
for Hyloris Pharmaceuticals SA.

Provide Operating Margin
for Hyloris Pharmaceuticals SA.

Provide Net Margin
for Hyloris Pharmaceuticals SA.

Provide FCF Margin
for Hyloris Pharmaceuticals SA.

Show all solvency ratios
for Hyloris Pharmaceuticals SA.

Provide D/E Ratio
for Hyloris Pharmaceuticals SA.

Provide D/A Ratio
for Hyloris Pharmaceuticals SA.

Provide Interest Coverage Ratio
for Hyloris Pharmaceuticals SA.

Provide Altman Z-Score Ratio
for Hyloris Pharmaceuticals SA.

Provide Quick Ratio
for Hyloris Pharmaceuticals SA.

Provide Current Ratio
for Hyloris Pharmaceuticals SA.

Provide Cash Ratio
for Hyloris Pharmaceuticals SA.

What is the historical Revenue growth
over the last 5 years for Hyloris Pharmaceuticals SA?

What is the historical Net Income growth
over the last 5 years for Hyloris Pharmaceuticals SA?

What is the current Free Cash Flow
of Hyloris Pharmaceuticals SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Hyloris Pharmaceuticals SA.

HYL

Balance Sheet

Current Portion of Long-Term Debt

Hyloris Pharmaceuticals SA
Current Portion of Long-Term Debt

Last Value

3-Years 3-Y CAGR

5-Years 5-Y CAGR

10-Years 10-Y CAGR

Quarterly

Annual

Adjust for Inflation

Hyloris Pharmaceuticals SA
Current Portion of Long-Term Debt Peer Comparison

Comparables:

UCB

TUB

Competitive Current Portion of Long-Term Debt Analysis
Latest Figures & CAGR of Competitors

	Current Portion of Long-Term Debt	CAGR 3Y	CAGR 5Y	CAGR 10Y
Hyloris Pharmaceuticals SA XBRU:HYL	Current Portion of Long-Term Debt €241k	CAGR 3-Years 74%	CAGR 5-Years 36%	CAGR 10-Years N/A
Ucb SA XBRU:UCB	Current Portion of Long-Term Debt €43m	CAGR 3-Years -52%	CAGR 5-Years -19%	CAGR 10-Years N/A
Financiere de Tubize SA XBRU:TUB	Current Portion of Long-Term Debt €31m	CAGR 3-Years N/A	CAGR 5-Years -10%	CAGR 10-Years -6%

What is Hyloris Pharmaceuticals SA's Current Portion of Long-Term Debt?

Current Portion of Long-Term Debt
241k EUR

Based on the financial report for Dec 31, 2023, Hyloris Pharmaceuticals SA's Current Portion of Long-Term Debt amounts to 241k EUR.

What is Hyloris Pharmaceuticals SA's Current Portion of Long-Term Debt growth rate?

Current Portion of Long-Term Debt CAGR 5Y
36%

Over the last year, the Current Portion of Long-Term Debt growth was 75%. The average annual Current Portion of Long-Term Debt growth rates for Hyloris Pharmaceuticals SA have been 74% over the past three years , 36% over the past five years .

Hyloris Pharmaceuticals SA
XBRU:HYL

Hyloris Pharmaceuticals SA
Current Portion of Long-Term Debt

Hyloris Pharmaceuticals SA
Current Portion of Long-Term Debt Peer Comparison

Competitive Current Portion of Long-Term Debt Analysis
Latest Figures & CAGR of Competitors

See Also

What is Hyloris Pharmaceuticals SA's Current Portion of Long-Term Debt?

Current Portion of Long-Term Debt
241k EUR

What is Hyloris Pharmaceuticals SA's Current Portion of Long-Term Debt growth rate?

Current Portion of Long-Term Debt CAGR 5Y
36%

Company

Help

Tools

Stocks

Hyloris Pharmaceuticals SA XBRU:HYL

Hyloris Pharmaceuticals SA Current Portion of Long-Term Debt

Hyloris Pharmaceuticals SA Current Portion of Long-Term Debt Peer Comparison

Competitive Current Portion of Long-Term Debt Analysis Latest Figures & CAGR of Competitors

See Also

What is Hyloris Pharmaceuticals SA's Current Portion of Long-Term Debt? Current Portion of Long-Term Debt 241k EUR

What is Hyloris Pharmaceuticals SA's Current Portion of Long-Term Debt growth rate? Current Portion of Long-Term Debt CAGR 5Y 36%

Company

Help

Tools

Stocks

Hyloris Pharmaceuticals SA
XBRU:HYL

Hyloris Pharmaceuticals SA
Current Portion of Long-Term Debt

Hyloris Pharmaceuticals SA
Current Portion of Long-Term Debt Peer Comparison

Competitive Current Portion of Long-Term Debt Analysis
Latest Figures & CAGR of Competitors

What is Hyloris Pharmaceuticals SA's Current Portion of Long-Term Debt?

Current Portion of Long-Term Debt
241k EUR

What is Hyloris Pharmaceuticals SA's Current Portion of Long-Term Debt growth rate?

Current Portion of Long-Term Debt CAGR 5Y
36%